Biosimilars are a prescription for better health.

Biosimilars could lead to over $130 billion in savings by 2025, giving 1.2 million patients access to needed medicines.

Learn More

GRx+Biosims 2021 | Virtual Conference

Hear the latest from top-in-their-field speakers and government officials, connect with peers from around the world and explore new learning tracks in the generics and biosimilars industry. November 8-10, 2021. Sign up for GRx+Biosims 2021 now and enjoy $300 in savings!

Watch Video

 

FDA Acting Commissioner to Speak at GRx+Biosims

Dr. Janet Woodcock will bring invaluable insights on generics and biosimilars during this public health emergency. Sign up for GRx+Biosims 2021 now and enjoy $300 in savings.

Register Now

secure our meds white paper

Roadmaps for Ensuring Patient Access to Generic and Biosimilar Medicines

This paper examines the challenges to market sustainability for generic and biosimilar medicines that have cleared the regulatory and patent hurdles to obtain FDA approval and launch into the U.S. market.

LEARN MORE

Browse our Resources

Hear more from experts on the potential of biosimilars and learn about Biosimilars Council efforts to increase biosimilar access for patients.

ALL RESOURCES

Want to keep up-to-date?

Enter your email address below and receive the Biosimilars Bulletin – our monthly newsletter with the most recent information on biosimilars in the United States.

  • This field is for validation purposes and should be left unchanged.

FDA Biosimilars Approvals

Find an up-to-date list of FDA approved biosimilars and launches.

Featured Reports & Resources

These resources provide answers around what biosimilars are, why they are important, how they can improve patient access, and how they can save the United States billions of dollars.

Biosimilars Council, Biosimilars Council
Biosimilars Council, Biosimilars Council
2020 Generics & Biosimilars Savings Report
failure to launch white paper

Recent Tweets